Mer­ck­'s wom­en's health spin­off goes pub­lic in NYSE de­but; A Hous­ton an­ti­body play­er scores fresh funds to chase tu­mors

Look­ing to free up a cash wind­fall and look­ing to stream­line the busi­ness, Mer­ck has long planned to slice away its women’s health busi­ness in­to a stand­alone spin­off. As of Thurs­day, that spin­off, dubbed Organon, is now a pub­lic en­ti­ty all its own.

Organon de­buted on the NYSE on Thurs­day, trad­ing un­der the tick­er $OGN. As a part of the spin­off, Mer­ck will re­ceive a $9 bil­lion spe­cial tax-free div­i­dend, mon­ey that the com­pa­ny has said it will like­ly use for a fu­ture ac­qui­si­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER